Mattson Financial Services LLC Buys Shares of 17,670 DexCom, Inc. (NASDAQ:DXCM)

Mattson Financial Services LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 17,670 shares of the medical device company’s stock, valued at approximately $2,003,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Centaurus Financial Inc. boosted its stake in shares of DexCom by 31.5% in the 2nd quarter. Centaurus Financial Inc. now owns 2,612 shares of the medical device company’s stock valued at $296,000 after purchasing an additional 625 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in DexCom by 533.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 36,510 shares of the medical device company’s stock worth $4,140,000 after purchasing an additional 30,743 shares in the last quarter. Cim LLC raised its holdings in DexCom by 4.3% in the 2nd quarter. Cim LLC now owns 10,578 shares of the medical device company’s stock worth $1,199,000 after purchasing an additional 432 shares in the last quarter. Sanctuary Advisors LLC bought a new position in DexCom in the 2nd quarter worth $1,395,000. Finally, Brown Financial Advisors bought a new position in DexCom in the 2nd quarter worth $1,236,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 1.7 %

DexCom stock opened at $67.10 on Thursday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The stock has a market cap of $26.68 billion, a price-to-earnings ratio of 43.29, a PEG ratio of 2.16 and a beta of 1.18. The company’s 50-day moving average price is $70.95 and its two-hundred day moving average price is $105.89.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the prior year, the firm posted $0.34 EPS. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, analysts expect that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,824 shares of company stock valued at $126,390. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DXCM. Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Wednesday. BTIG Research dropped their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Oppenheimer dropped their price objective on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $145.00 price objective on shares of DexCom in a report on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $112.25.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.